The U.S. Food and Drug Administration (FDA) is allowing medical artificial intelligence (AI) software developer CuraCloud's new deep learning-based algorithm to be used for the detection and prioritization of incidental pneumonia findings associated with COVID-19. The findings stem from noncontrast chest CT images.
The firm's CuraRad-ICH algorithm analyzes noncontrast head CT images for the detection and prioritization of intracranial hemorrhage patients, but CuraCloud is enhancing its software to process chest CT exams. The results can be used to enable the algorithm to notify the radiology worklist that the image includes findings suggestive of pneumonia associated with COVID-19.
The enhancement is designed to improve clinical workflow through integration with PACS and enterprise worklist applications, CuraCloud said. The firm is also seeking collaborators to further develop its triage software.
